Rezvani Amir H, Kholdebarin Ehsan, Cauley Marty C, Dawson Elizabeth, Levin Edward D
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.
Pharmacol Biochem Behav. 2009 Mar;92(1):141-6. doi: 10.1016/j.pbb.2008.11.005. Epub 2008 Nov 17.
Methylphenidate is widely used as a treatment option for attention deficit hyperactivity disorder. In animal models of attentional impairment, it is an important validation to determine whether this clinically effective treatment attenuates deficits. The purpose of the current study was to determine whether methylphenidate can diminish attentional impairment induced by three pharmacological agents with different mechanisms of action: scopolamine, mecamylamine, and dizocilpine. Female rats were trained on an operant visual signal detection task. Ten min before the test, the rats were injected subcutaneously with methylphenidate (0, 0.1, 0.3 mg/kg), scopolamine (0, 0.005, 0.01 mg/kg), mecamylamine (0, 2, 4 mg/kg), dizocilpine (0, 0.025, 0.05 mg/kg) or combinations of methylphenidate with these drugs. In each of the experiments, all rats received every treatment in a repeated measures counterbalanced order. Correction rejection accuracy was impaired by all three of the antagonists and these effects were attenuated by methylphenidate. Both scopolamine at 0.01 and dizocilpine at 0.05 mg/kg significantly impaired percent correct rejection choice accuracy, an effect that was ameliorated by methylphenidate. Mecamylamine (4 mg/kg) impaired attentional performance by reducing percent hit and percent correct rejection. Co-administration of methylphenidate failed to significantly affect the mecamylamine-induced attentional impairment. Methylphenidate alone at 0.3 mg/kg significantly improved percent hit choice accuracy only in low-performing rats in one experiment, an effect which was reversed by scopolamine. These data show that methylphenidate effectively reverses the attentional impairment caused by scopolamine and dizocilpine. These findings further validate the operant visual signal detection task for assessing attentional impairments and their reversal.
哌醋甲酯被广泛用作治疗注意力缺陷多动障碍的一种选择。在注意力损伤的动物模型中,确定这种临床有效的治疗方法是否能减轻缺陷是一项重要的验证。本研究的目的是确定哌醋甲酯是否能减轻由三种作用机制不同的药物引起的注意力损伤:东莨菪碱、美加明和地卓西平。对雌性大鼠进行操作性视觉信号检测任务训练。在测试前10分钟,给大鼠皮下注射哌醋甲酯(0、0.1、0.3毫克/千克)、东莨菪碱(0、0.005、0.01毫克/千克)、美加明(0、2、4毫克/千克)、地卓西平(0、0.025、0.05毫克/千克)或哌醋甲酯与这些药物的组合。在每个实验中,所有大鼠都以重复测量的平衡顺序接受每种治疗。所有三种拮抗剂均损害了校正拒绝准确性,而哌醋甲酯减轻了这些影响。0.01毫克/千克的东莨菪碱和0.05毫克/千克的地卓西平均显著损害了正确拒绝选择准确性百分比,哌醋甲酯改善了这一效应。美加明(4毫克/千克)通过降低命中百分比和正确拒绝百分比损害了注意力表现。哌醋甲酯与美加明联合给药未能显著影响美加明引起的注意力损伤。仅在一个实验中,0.3毫克/千克的哌醋甲酯单独给药仅在低表现大鼠中显著提高了命中选择准确性百分比,而东莨菪碱逆转了这一效应。这些数据表明,哌醋甲酯有效地逆转了由东莨菪碱和地卓西平引起的注意力损伤。这些发现进一步验证了操作性视觉信号检测任务在评估注意力损伤及其逆转方面的作用。